Cargando…

Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients

BACKGROUND: Heterozygous familial hypercholesterolemia (HFH) is an autosomal dominant genetic disorder leading to a lifetime exposure to high low-density lipoprotein cholesterol (LDL-c) level and an increased risk of premature atherosclerotic cardiovascular disease (ASCVD). We evaluate the effect of...

Descripción completa

Detalles Bibliográficos
Autores principales: Matta, Anthony, Rabès, Jean Pierre, Taraszkiewicz, Dorota, Carrié, Didier, Roncalli, Jérôme, Ferrières, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395089/
https://www.ncbi.nlm.nih.gov/pubmed/37539087
http://dx.doi.org/10.3389/fcvm.2023.1182554
_version_ 1785083514299875328
author Matta, Anthony
Rabès, Jean Pierre
Taraszkiewicz, Dorota
Carrié, Didier
Roncalli, Jérôme
Ferrières, Jean
author_facet Matta, Anthony
Rabès, Jean Pierre
Taraszkiewicz, Dorota
Carrié, Didier
Roncalli, Jérôme
Ferrières, Jean
author_sort Matta, Anthony
collection PubMed
description BACKGROUND: Heterozygous familial hypercholesterolemia (HFH) is an autosomal dominant genetic disorder leading to a lifetime exposure to high low-density lipoprotein cholesterol (LDL-c) level and an increased risk of premature atherosclerotic cardiovascular disease (ASCVD). We evaluate the effect of a causative genetic variant to predict ASCVD in HFH patients undergoing treatment. MATERIALS AND METHODS: A retrospective cohort was conducted on 289 patients with possible, probable, and definite diagnosis of HFH according to Dutch Lipid Clinic Network Score and in whom DNA analyses were performed and mean LDL-c level was above 155 mg/dl. The study population was divided into groups based on the presence or not of a causative variant (pathogenic or likely pathogenic). We observed each of the study’s participants for the occurrence of ASCVD. RESULTS: A causative variant was detected in 42.2% of study participants, and ASCVD has occurred in 21.5% of HFH patients. The incidence of ASCVD (27% vs. 17.4%, p = 0.048) and the mean of LDL-c under an optimal medical treatment (226 ± 59 mg/dl vs. 203 ± 37 mg/dl, p = 0.001) were higher in HFH-causative variant carriers than others. After adjusting on confounders, ASCVD was positively associated with LDL-c level [OR = 2.347; 95% (1.305–4.221), p = 0.004] and tends toward a negative association with HDL-c level [OR = 0.140; 95% (0.017–1.166), p = 0.059]. There is no more association between the detection of a causative variant and the occurrence of ASCVD [OR = 1.708; 95% (0.899–3.242), p = 0.102]. Kaplan Meier and log rank test showed no significant differences in event-free survival analysis between study groups (p = 0.523). CONCLUSION: In this study population under medical care, it seems that the presence of a causative variant did not represent an independent predictor of adverse cardiovascular outcomes in HFH patients, and LDL-c level played an undisputable causal role.
format Online
Article
Text
id pubmed-10395089
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103950892023-08-03 Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients Matta, Anthony Rabès, Jean Pierre Taraszkiewicz, Dorota Carrié, Didier Roncalli, Jérôme Ferrières, Jean Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Heterozygous familial hypercholesterolemia (HFH) is an autosomal dominant genetic disorder leading to a lifetime exposure to high low-density lipoprotein cholesterol (LDL-c) level and an increased risk of premature atherosclerotic cardiovascular disease (ASCVD). We evaluate the effect of a causative genetic variant to predict ASCVD in HFH patients undergoing treatment. MATERIALS AND METHODS: A retrospective cohort was conducted on 289 patients with possible, probable, and definite diagnosis of HFH according to Dutch Lipid Clinic Network Score and in whom DNA analyses were performed and mean LDL-c level was above 155 mg/dl. The study population was divided into groups based on the presence or not of a causative variant (pathogenic or likely pathogenic). We observed each of the study’s participants for the occurrence of ASCVD. RESULTS: A causative variant was detected in 42.2% of study participants, and ASCVD has occurred in 21.5% of HFH patients. The incidence of ASCVD (27% vs. 17.4%, p = 0.048) and the mean of LDL-c under an optimal medical treatment (226 ± 59 mg/dl vs. 203 ± 37 mg/dl, p = 0.001) were higher in HFH-causative variant carriers than others. After adjusting on confounders, ASCVD was positively associated with LDL-c level [OR = 2.347; 95% (1.305–4.221), p = 0.004] and tends toward a negative association with HDL-c level [OR = 0.140; 95% (0.017–1.166), p = 0.059]. There is no more association between the detection of a causative variant and the occurrence of ASCVD [OR = 1.708; 95% (0.899–3.242), p = 0.102]. Kaplan Meier and log rank test showed no significant differences in event-free survival analysis between study groups (p = 0.523). CONCLUSION: In this study population under medical care, it seems that the presence of a causative variant did not represent an independent predictor of adverse cardiovascular outcomes in HFH patients, and LDL-c level played an undisputable causal role. Frontiers Media S.A. 2023-07-19 /pmc/articles/PMC10395089/ /pubmed/37539087 http://dx.doi.org/10.3389/fcvm.2023.1182554 Text en © 2023 Matta, Rabès, Taraszkiewicz, Carrié, Roncalli and Ferrières. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Matta, Anthony
Rabès, Jean Pierre
Taraszkiewicz, Dorota
Carrié, Didier
Roncalli, Jérôme
Ferrières, Jean
Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
title Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
title_full Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
title_fullStr Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
title_full_unstemmed Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
title_short Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
title_sort effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395089/
https://www.ncbi.nlm.nih.gov/pubmed/37539087
http://dx.doi.org/10.3389/fcvm.2023.1182554
work_keys_str_mv AT mattaanthony effectofcausativegeneticvariantsonatheroscleroticcardiovasculardiseaseinheterozygousfamilialhypercholesterolemiapatients
AT rabesjeanpierre effectofcausativegeneticvariantsonatheroscleroticcardiovasculardiseaseinheterozygousfamilialhypercholesterolemiapatients
AT taraszkiewiczdorota effectofcausativegeneticvariantsonatheroscleroticcardiovasculardiseaseinheterozygousfamilialhypercholesterolemiapatients
AT carriedidier effectofcausativegeneticvariantsonatheroscleroticcardiovasculardiseaseinheterozygousfamilialhypercholesterolemiapatients
AT roncallijerome effectofcausativegeneticvariantsonatheroscleroticcardiovasculardiseaseinheterozygousfamilialhypercholesterolemiapatients
AT ferrieresjean effectofcausativegeneticvariantsonatheroscleroticcardiovasculardiseaseinheterozygousfamilialhypercholesterolemiapatients